BACKGROUND: In the recent years, surgical resection with pre- and/or postoperative chemotherapy has markedly improved the survival rate of hepatoblastoma patients. We herein report the results of patients treated with the current protocol of the Japanese Study Group for Pediatric Liver Tumor, JPLT-2. METHODS: A total of 279 patients with malignant liver tumor were enrolled in JPLT-2. Data from 212 hepatoblastoma cases were analyzed. PRETEXT I patients were treated with primary resection followed by low doses of cisplatin-pirarubicin (tetrahydropyranyl-adriamycin). Otherwise, patients received preoperative cisplatin-pirarubicin (CITA), followed by surgery and postoperative chemotherapy. Ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC) were given as a salvage treatment. High-dose chemotherapy with hematopoietic stem cell transplantation (SCT) was reserved for patients with metastatic diseases. RESULTS: The 5-year overall survival rate (OS) in non-metastatic cases was 100% for PRETEXT I, 87.1% for PRETEXT II, 89.7% for PRETEXT III, and 78.3% for PRETEXT IV. The 5-year OS in metastatic cases was 43.9%. The outcome in non-metastatic PRETEXT IV cases was markedly improved, while the results of metastatic tumors remained poor. CONCLUSIONS: JPLT-2 protocol achieved satisfactory survival among children with non-metastatic hepatoblastoma. New approaches are needed for patients with metastatic diseases.
BACKGROUND: In the recent years, surgical resection with pre- and/or postoperative chemotherapy has markedly improved the survival rate of hepatoblastomapatients. We herein report the results of patients treated with the current protocol of the Japanese Study Group for Pediatric Liver Tumor, JPLT-2. METHODS: A total of 279 patients with malignant liver tumor were enrolled in JPLT-2. Data from 212 hepatoblastoma cases were analyzed. PRETEXT I patients were treated with primary resection followed by low doses of cisplatin-pirarubicin (tetrahydropyranyl-adriamycin). Otherwise, patients received preoperative cisplatin-pirarubicin (CITA), followed by surgery and postoperative chemotherapy. Ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC) were given as a salvage treatment. High-dose chemotherapy with hematopoietic stem cell transplantation (SCT) was reserved for patients with metastatic diseases. RESULTS: The 5-year overall survival rate (OS) in non-metastatic cases was 100% for PRETEXT I, 87.1% for PRETEXT II, 89.7% for PRETEXT III, and 78.3% for PRETEXT IV. The 5-year OS in metastatic cases was 43.9%. The outcome in non-metastatic PRETEXT IV cases was markedly improved, while the results of metastatic tumors remained poor. CONCLUSIONS: JPLT-2 protocol achieved satisfactory survival among children with non-metastatic hepatoblastoma. New approaches are needed for patients with metastatic diseases.
Authors: Daniël C Aronson; J Marco Schnater; Chris R Staalman; Gerrit J Weverling; Jack Plaschkes; Giorgio Perilongo; Julia Brown; Angela Phillips; Jean-Bernard Otte; Piotr Czauderna; Gordon MacKinlay; Anton Vos Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Lisa R Bomgaars; Mark Bernstein; Mark Krailo; Richard Kadota; Soma Das; Zhengjia Chen; Peter C Adamson; Susan M Blaney Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Giorgio Perilongo; Rudolf Maibach; Elisabeth Shafford; Laurence Brugieres; Penelope Brock; Bruce Morland; Beatriz de Camargo; Jozsef Zsiros; Derek Roebuck; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Eva Widing; Veronique Laithier; Jack Plaschkes; Jon Pritchard; Marcello Scopinaro; Gordon MacKinlay; Piotr Czauderna Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: J B Otte; J Pritchard; D C Aronson; J Brown; P Czauderna; R Maibach; G Perilongo; E Shafford; J Plaschkes Journal: Pediatr Blood Cancer Date: 2004-01 Impact factor: 3.167
Authors: S Suita; T Tajiri; H Takamatsu; H Mizote; A Nagasaki; Y Inomata; T Hara; J Okamura; S Miyazaki; K Kawakami; H Eguchi; M Tsuneyoshi Journal: J Pediatr Surg Date: 2004-02 Impact factor: 2.545
Authors: K Tanaka; S Uemoto; Y Tokunaga; S Fujita; K Sano; T Nishizawa; H Sawada; I Shirahase; H J Kim; Y Yamaoka Journal: Ann Surg Date: 1993-01 Impact factor: 12.969
Authors: J Hara; Y Osugi; H Ohta; Y Matsuda; K Nakanishi; K Takai; H Fujisaki; S Tokimasa; M Fukuzawa; A Okada; S Okada Journal: Bone Marrow Transplant Date: 1998-07 Impact factor: 5.483
Authors: Alexander J Towbin; Rebecka L Meyers; Helen Woodley; Osamu Miyazaki; Christopher B Weldon; Bruce Morland; Eiso Hiyama; Piotr Czauderna; Derek J Roebuck; Greg M Tiao Journal: Pediatr Radiol Date: 2018-02-09